Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Phentermine,Topiramate
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
VIVUS Launches QSYMIA® in the United Arab Emirates
Details : Qsymia (phentermine/topiramate) is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity.
Product Name : Qsymia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 10, 2025
Lead Product(s) : Phentermine,Topiramate
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Phentermine,Topiramate
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
VIVUS Shares Significant Regulatory Update On QSYMIA®
Details : Qsymia (phentermine/topiramate) is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity.
Product Name : Qsymia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 28, 2024
Lead Product(s) : Phentermine,Topiramate
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Phentermine,Topiramate
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
VIVUS Announces Label Update for QSYMIA®
Details : Qsymia (phentermine/topiramate) is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity.
Product Name : Qsymia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 23, 2024
Lead Product(s) : Phentermine,Topiramate
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Topiramate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Glenmark Pharma gets USFDA nod for seizure treatment drug
Details : Topamax-Generic (topiramate) is a GABA-A receptor; anion channel positive modulator, small molecule which is indicated for the treatment of epilepsy and migraine.
Product Name : Topamax-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 17, 2024
Lead Product(s) : Topiramate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Phentermine,Topiramate
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase IV
Sponsor : Mayo Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : QSIVA is a combination of phentermine, a sympathomimetic amine anorectic and topiramate extended-release, an antiepileptic drug. It is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adul...
Product Name : Qsymia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 17, 2023
Lead Product(s) : Phentermine,Topiramate
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase IV
Sponsor : Mayo Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Topiramate
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Forge Biologics
Deal Size : Undisclosed
Deal Type : Partnership
Details : The partnership will advance Eikonoklastes’ AAV-based gene therapy, ET-101, into clinical trials for the treatment of patients with amyotrophic lateral sclerosis (ALS).
Product Name : ET-101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 29, 2022
Lead Product(s) : Topiramate
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Forge Biologics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Topiramate
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The company’s 1st-in-class gene therapy ET-101 has been engineered to overexpress Caveolin-1, which organizes and regulates synaptic receptors essential for neuromuscular signaling and function.
Product Name : ET-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 11, 2022
Lead Product(s) : Topiramate
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Topiramate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The U.S. FDA has approved Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg, the generic version of Qudexy®1 XR Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg, of Upsher-Smith Laboratories, LLC.
Product Name : Topamax-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 02, 2021
Lead Product(s) : Topiramate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Topiramate
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eton Pharmaceuticals Submits New Drug Application to the FDA for Topiramate Oral Solution (ET-101)
Details : Marketing Application for ET-101 was submitted for monotherapy to treat primary general tonic-clonic seizures in patients at least two years old, adjunctive therapy for treatment of partial-onset seizures, and as preventative treatment of migraine in pat...
Product Name : ET-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 10, 2020
Lead Product(s) : Topiramate
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Topiramate
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eton Pharmaceuticals Reports Positive Study Results for ET-101
Details : Results demonstrated bioequivalence to the currently approved oral solid formulation.
Product Name : ET-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 17, 2020
Lead Product(s) : Topiramate
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable